Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teva Pharma Japan Aims at Early Launch of Biosimilars Marketed Overseas in Japan: President Shimada
April 18, 2012
- Dainippon Sumitomo Pharma Files for Supplemental Approval of Surepost in Combination Therapy with Biguanides and with Thiazolidinediones
April 18, 2012
- Hiring of New Pharmacists Sluggish Due to Decreasing Numbers of Applicants, Tough Competition: Major Dispensing Pharmacies
April 18, 2012
- Eisai Launches Insomnia Treatment Lunesta
April 18, 2012
- Daiichi Sankyo Launches Ranmark for Treatment of Bone Lesions Associated with Cancer; AZ to Copromote Product
April 18, 2012
- Eli Lilly Japan Pinning New Hopes on Solanezumab; Will the Introduction of Medicoeconomic Assessments Help?
April 18, 2012
- MediBIC and Kobe University Hospital to Jointly Form Conference on Pharmacogenomics
April 17, 2012
- JCSOA to Draw Up Guideline for Coping with Business Conflicts this Year
April 17, 2012
- Actelion Receives Approval for NPC Treatment
April 17, 2012
- Ajinomoto Pharmaceuticals to Distribute Lentinan from July: Ajinomoto, Taiho
April 17, 2012
- Generic Names Used in 25% of Prescriptions Issued by GPs: Nihon Chouzai
April 17, 2012
- National, Rosai Hospitals to Buy 9,000 Products in First Joint Purchasing, HQ to Buy Generics by Bulk
April 16, 2012
- Elmed Eisai Found to Make Good Impression on Pharmacists: Survey
April 16, 2012
- Over 60% of Drug Makers Increased Hiring of New Graduates in 2012: Jiho Survey
April 16, 2012
- Ain Pharmaciez to Introduce Electronic Drug Notebooks at All Its Group Stores in July
April 16, 2012
- Takeda to Acquire URL Pharma, Boost US Business Base Through Field of Gout
April 13, 2012
- ECI to Initiate Clinical Research for Cancer Therapy ECI301
April 13, 2012
- AnGes MG to Codevelop High Blood Pressure Treatment Oral Vaccine with Korean Company
April 13, 2012
- US Subsidiary’s CEO Resigns: DSP
April 13, 2012
- AnGes MG Obtains Pharmaceutical Use Patent in Japan for NF-κB Decoy Oligo
April 13, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…